AE Kitabchi, E Kaminska, JN Fisher, A … - The American journal of the medical sciences, 2000 - journals.lww.com Skip Navigation Links Home > March 2000 - Volume 319 - Issue 3 > Comparative
Efficacy and Potency of Long-Term Therapy with G... ... From the Department of
Medicine, the Clinical Research Center, and the Department of Preventive ... Cited by 14 - Related articles - BL Direct - All 4 versions
[CITATION] the LM Study Group: Lower incidence of nocturnal hypoglycemia during treatment with a …
V Fonseca - Current Medical Research and Opinion®, 2003 - informahealthcare.com Measurement of glycosylated hemoglobin (HbA1C) remains the gold standard for the
assessment of glycemic control in patients with type 2 diabetes. Recent
investigations have studied the correlations between HbA1C levels and other ... Cited by 31 - Related articles - BL Direct - All 8 versions
N Tentolouris, E Boutati, N Karambakalis, D … - Nutrition, Metabolism and Cardiovascular Diseases, 2005 - Elsevier As expected, there was a significant reduction in postprandial glycaemia after
nateglinide administration compared to placebo (P < 0.001). Plasma insulin
levels were significantly higher after nateglinide than after placebo (P = ... Cited by 8 - Related articles - BL Direct - All 8 versions
O Schmitz, S Lund, PH Andersen, M Jønler, N … - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—The study was a double-blind, randomized,
parallel-group trial in 19 antidiabetic agent-naive subjects with type 2
diabetes (mean age 58 years, known duration of diabetes 3.5 years, HbA 1c ... Cited by 23 - Related articles - BL Direct - All 5 versions
S Del Prato, RJ Heine, L Keilson, C Guitard … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Retrospective subgroup analyses were performed on
pooled data from all completed nateglinide studies (12 randomized, double blind
trials and 1 open trial) in patients with type 2 diabetes. A total of 3,702 ... Cited by 26 - Related articles - BL Direct - All 5 versions
C Black, P Donnelly, L McIntyre, PL Royle, … - Cochrane database of systematic reviews (Online), 2007 - ncbi.nlm.nih.gov BACKGROUND: In type 2 diabetes mellitus, impairment of insulin secretion is an
important component of the disease. Meglitinide analogues are a class of oral
hypoglycaemic agents that increase insulin secretion, in particular, during ... Cited by 14 - Related articles
